白蛋白结合型紫杉醇联合铂类化疗方案对晚期非小细胞肺癌的疗效及毒性分析  

Efficacy and toxicity analysis of albumin-bound paclitaxel combined with platinum-based chemotherapy regimen on advanced non-small cell lung cancer

作　　者：刘瑜 杜丽 赵彬 LIU Yu;DU Li;ZHAO Bin(Department of Oncology,Guangyuan Central Hospital,Guangyuan,Sichuan,628000,China)

机构地区：[1]广元市中心医院肿瘤科,四川广元628000

出　　处：《当代医学》2025年第1期1-5,共5页Contemporary Medicine

摘　　要：目的探究白蛋白结合型紫杉醇联合铂类化疗方案对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及毒性。方法选取2021年1月至2023年1月广元市中心医院收治的100例晚期NSCLC患者作为研究对象,按照随机数字表法分为对照组与研究组,每组50例。对照组应用紫杉醇联合顺铂治疗,研究组应用白蛋白结合型紫杉醇联合顺铂治疗。比较两组临床疗效、肿瘤标志物[癌胚抗原(carcinoembryonic antigen,CEA)、高迁移率族蛋白B1(high mobility group protein B1,HMGB1)、糖类抗原125(carbohydrate antigen 125,CA125)]、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、生命质量[欧洲癌症研究治疗组织癌症患者生命质量测定量表(European Organization for Research and Treatment of Cancer quality of life questionnaire core 30,EORTC QLQ-C30)]及毒副作用发生情况。结果治疗后,两组均无完全缓解病例,研究组治疗总有效率为44.00%,高于对照组的26.00%,但整体疗效比较差异无统计学意义;治疗后,两组CEA、HMGB1、CA125水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD4^(+)水平及CD4^(+)/CD8^(+)均低于治疗前,CD8^(+)水平均高于治疗前,差异有统计学意义(P<0.05),但组间比较差异无统计学意义;治疗后,两组疲劳、恶心呕吐、疼痛评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗期间两组无5级病例,研究组毒副作用低于对照组,差异有统计学意义(P<0.05)。结论白蛋白结合型紫杉醇联合铂类化疗方案治疗晚期NSCLC患者疗效显著,可有效降低其血清中肿瘤标志物水平,增强患者机体免疫功能,降低毒副作用,提升患者生命质量。Objective To explore the efficacy and toxicity of albumin-bound paclitaxel combined with platinum-based chemotherapy regimen on advanced non-small cell lung cancer(NSCLC).Methods A total of 100 patients with advanced NSCLC admitted to Guangyuan Central Hospital from January 2021 to January 2023 were selected as the study subjects,and they were divided into the control group and the study group according to random number table method,with 50 cases in each group.The control group was treated with paclitaxel combined with cisplatin,and the study group was treated with albumin-bound paclitaxel combined with cisplatin.The clinical efficacy,tumor marker(carcinoembryonic antigen[CEA],high mobility group protein B1[HMGB1],carbohydrate antigen 125[CA125]),immune function indicators(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),quality of life(European Organization for Research and Treatment of Cancer quality scale of life questionnaire core 30[EORTC QLQ-C30])and occurrence of toxic and side effects were compared between the two groups.Results After treatment,there were no complete remission cases in the two groups,the total effective rate in the study group was 44.00%,which was higher than 26.00%in the control group,but there was no statistically significant difference in overall efficacy;after treatment,CEA,HMGB1 and CA125 levels of the two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05);after treatment,CD4^(+)level and CD4^(+)/CD8^(+)of the two groups were lower than before treatment,and CD8^(+)was higher than before treatment,the differences were statistically significant(P<0.05),but there was no statistical significance between the two groups;after treatment,the scores of fatigue,nausea,vomiting and pain of the two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05);there were no grade 5 cases in the two groups during treatment,and the to

关 键 词：白蛋白结合型紫杉醇 晚期非小细胞肺癌 毒性分析 

分 类 号：R734.2[医药卫生—肿瘤]